Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 1/20 | 0.44 |
| ▸ | GJA1 | P17302 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | AGXT | P21549 | 2/20 | 0.36 |
| ▸ | APP | P05067 | 2/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628196 | 0.88 | GJB2 (0.43) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL6809981 | 0.86 | SSTR4 (0.49) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL15377840 | 0.85 | GJB2 (0.41) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL5941739 | 0.84 | SSTR4 (0.44) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL9101113 | 0.82 | SSTR4 (0.40) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL8625319 | 0.82 | GJB2 (0.41) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL14747303 | 0.82 | GJB2 (0.47) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL5027889 | 0.81 | GJB2 (0.51) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL5027888 | 0.81 | GJB2 (0.51) | GJB2GJA1SSTR4SSTR1SSTR2 | |
| SCHEMBL17267495 | 0.80 | GJB2 (0.46) | GJB2GJA1SSTR4SSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512158-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2016-12-06 | — | — | US | disclosed |
| EP-2089051-B1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9090643-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2015-07-28 | — | — | US | disclosed |
| US-8916169-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes | NEWLINK GENETICS CORPORATION (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130178613-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164319-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164318-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NewLink Genetics Corp. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8357777-B2 | Enhanced immunogenicity of tumor associated antigens by addition of αgal epitopes | NEWLINK GENETICS (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | NEWLINK GENETICS (US) | 2012-01-05 | — | — | US | disclosed |
| US-7998486-B2 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | NEWLINK GENETICS CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090060930-A1 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | NEWLINK GENETICS | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164319-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | GJB2 3987/4885GJA1 3114/4885SSTR4 2874/4885 |
| US-20130178613-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | GJB2 3987/4885GJA1 3114/4885SSTR4 2874/4885 |
| US-20090060930-A1 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes | ENGASE, FUT5, FUT6 | GJB2 3987/4885GJA1 3114/4885SSTR4 2874/4885 |
| US-20120003251-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, GALE, FUT5 | GJB2 4221/4885GJA1 3373/4885SSTR4 2914/4885 |
| US-20130164318-A1 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES | ENGASE, FUT5, FUT6 | GJB2 3987/4885GJA1 3114/4885SSTR4 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.